Tomasz Ahrends

Tomasz Ahrends

Auto-generated profile, based on publicly available information

Tomasz Ahrends

Laboratory of Mucosal Immunology, The Rockefeller University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2018 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
JBJannie Borst
Jannie Borst
TATomasz Ahrends
Tomasz Ahrends
NBNikolina Bąbała
Nikolina Bąbała
CMCornelis J. M. Melief
Cornelis J. M. Melief
WKWolfgang Kastenmüller
Wolfgang Kastenmüller

1 November 2017 in Immunity
Verified
Journal Article
Closed access
TATomasz Ahrends
Tomasz Ahrends
ASAldo Spanjaard
Aldo Spanjaard
BPBas Pilzecker
Bas Pilzecker
NBNikolina Bąbała
Nikolina Bąbała
ABAstrid Bovens
Astrid Bovens
JBJannie Borst
Jannie Borst

9 January 2020 in Cell
Verified
Journal Article
Closed access
FMFanny Matheis
Fanny Matheis
PMPaul A. Muller
Paul A. Muller
CGChristina L. Graves
Christina L. Graves
IGIlana Gabanyi
Ilana Gabanyi
ZKZachary J. Kerner
Zachary J. Kerner
DMDaniel Mucida
Daniel Mucida

27 April 2018 in Immunology
Verified
Journal Article
Closed access
PDF file
TATomasz Ahrends
Tomasz Ahrends
JBJannie Borst
Jannie Borst

4 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TATomasz Ahrends
Tomasz Ahrends
JBJulia Busselaar
Julia Busselaar
TSTesa M. Severson
Tesa M. Severson
NBNikolina Bąbała
Nikolina Bąbała
EVEvert de Vries
Evert de Vries
JBJannie Borst
Jannie Borst
CD4+ T cell help is required for the generation of CD8+ cytotoxic T lymphocyte (CTL) memory. Here, we use genome-wide analyses to show how CD4+ T cell help delivered during priming promotes memory differentiation of CTLs. Help signals enhance IL-15-dependent maintenance of central memory T (TCM) cells. More importantly, help signals regulate the size and function of the effector memory T (TEM) cell pool. Helped TEM cells produce Granzyme B and IFNγ upon antigen-independent, innate-like recall by IL-12 and IL-18. In addition, helped memory CTLs express the effector program characteristic of helped primary CTLs upon recall with MHC class I-restricted antigens, likely due to epigenetic imprinting and sustained mRNA expression of effector genes. Our data thus indicate that during priming, CD4+ T cell help optimizes CTL memory by creating TEM cells with innate and help-independent antigen-specific recall capacities.

12 May 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
TATomasz Ahrends
Tomasz Ahrends
NBNikolina Bąbała
Nikolina Bąbała
YXYanling Xiao
Yanling Xiao
HYHideo Yagita
Hideo Yagita
HEHans van Eenennaam
Hans van Eenennaam
JBJannie Borst
Jannie Borst
While showing promise, vaccination strategies to treat cancer require further optimization. Likely barriers to efficacy involve cancer-associated immunosuppression and peripheral tolerance, which limit the generation of effective vaccine-specific cytotoxic T lymphocytes (CTL). Because CD4+ T cells improve CTL responsiveness, next-generation vaccines include helper epitopes. Here, we demonstrate in mice how CD4+ T-cell help optimizes the CTL response to a clinically relevant DNA vaccine engineered to combat human papillomavirus–expressing tumors. Inclusion of tumor-unrelated helper epitopes greatly increased CTL priming, effector, and memory T-cell programming. CD4+ T-cell help optimized the CTL response in all these aspects via CD27/CD70 costimulation. Notably, administration of an agonistic CD27 antibody could largely replace helper epitopes in promoting primary and memory CTL responses, acting directly on CD8+ T cells. CD27 agonism improved efficacy of the vaccine without helper epitopes, more so than combined PD-1 and CTLA-4 blockade. Combining CD27 agonism with CTLA-4 blockade improved vaccine-induced CTL priming and tumor infiltration, but only combination with PD-1 blockade was effective at eradicating tumors, thereby fully recapitulating the effect of CD4+ T-cell help on vaccine efficacy. PD-1 blockade alone did not affect CTL priming or tumor infiltration, so these results implied that it cooperated with CD4+ T-cell help by alleviating immune suppression against CTL in the tumor. Helper epitope inclusion or CD27 agonism did not stimulate regulatory T cells, and vaccine efficacy was also improved by CD27 agonism in the presence of CD4+ T-cell help. Our findings provide a preclinical rationale to apply CD27 agonist antibodies, either alone or combined with PD-1 blockade, to improve the therapeutic efficacy of cancer vaccines and immunotherapy generally. Cancer Res; 76(10); 2921–31. ©2016 AACR.